학술논문
The PI3Kd-selective inhibitor idelalisib minimally interferes with immune effector function mediated by rituximab or obinutuzumab and significantly augments B cell depletion in vivo
Document Type
Article
Author
Source
In: Journal of Immunology . (Journal of Immunology, 1 April 2018, 200(7):2304-2312)
Subject
Language
English
ISSN
15506606
00221767
00221767